The DONSON gene encodes the downstream neighbor of SON, a replisome component that stabilizes the replication fork during replication. A severe form of microcephalic dwarfism, microcephaly-micromelia syndrome (MIMIS), has been recently associated with DONSON biallelic loss of function. Affected fetuses suffer severe growth restriction, microcephaly, and variable limb malformations which result in intrauterine or perinatal death. All described fetuses carried a homozygous founder mutation (c.1047-9A>G), a splice-altering variant that leads to transcript degradation. We evaluated 2 newborns from a consanguineous Emirati family with severe microcephaly, micromelia, craniofacial dysmorphism, and skeletal abnormalities; both died shortly after birth. Here, we report the second homozygous loss-of-function variant (c.763C>T) in DONSON causing MIMIS, and we provide detailed clinical description of this very rare disorder. In addition, we review all MIMIS cases in the literature and summarize the striking features of this phenotype. This manuscript is aimed to increase the clinical understanding of this rare, extremely severe disorder and encourage clinical and molecular geneticists to consider screening for DONSON loss-of-function variants in families with recurrent pregnancy loss and/or perinatal deaths.

Keywords:
Intrauterine growth restriction, Microcephaly-micromelia syndrome, Replication fork stability
1.
Abdelrahman HA, Al-Shamsi A, John A, Hertecant J, Lootah A, et al: A recessive truncating variant in thrombospondin-1 domain containing protein 1 gene THSD1 is the underlying cause of nonimmune hydrops fetalis, congenital cardiac defects, and haemangiomas in four patients from a consanguineous family. Am J Med Genet A 176:1996-2003 (2018).
2.
Casper AM, Durkin SG, Arlt MF, Glover TW: Chromosomal instability at common fragile sites in Seckel syndrome. Am J Hum Genet 75:654-660 (2004).
3.
Evrony GD, Cordero DR, Shen J, Partlow JN, Yu TW, et al: Integrated genome and transcriptome sequencing identifies a noncoding mutation in the genome replication factor DONSON as the cause of microcephaly-micromelia syndrome. Genome Res 27:1323-1335 (2017).
4.
Ives EJ, Houston CS: Autosomal recessive microcephaly and micromelia in Cree Indians. Am J Med Genet 7:351-360 (1980).
5.
Rauch A, Thiel CT, Schindler D, Wick U, Crow YJ, et al: Mutations in the pericentrin (PCNT) gene cause primordial dwarfism. Science 319:816-819 (2008).
6.
Reynolds JJ, Bicknell LS, Carroll P, Higgs MR, Shaheen R, et al: Mutations in DONSON disrupt replication fork stability and cause microcephalic dwarfism. Nat Genet 49:537-549 (2017).
7.
Richards S, Aziz N, Bale S, Bick D, Das S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405-424 (2015).
8.
Schulz S, Mensah MA, de Vries H, Fröber R, Romeike B, et al: Microcephaly, short stature, and limb abnormality disorder due to novel autosomal biallelic DONSON mutations in two German siblings. Eur J Hum Genet 26:1282-1287 (2018).
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.